TickerTalks
Browse all tickers →
TickerTalks›$ELTX
ELELTX

Elicio Therapeutics, Inc.

Hot onTrending downwardX chatter spiked vs its recent normMoving on elevated volume
$ELTX·$90M·Biotechnology·Healthcare
$3.85-18.3%YTD-52.3%1Y-51.6%
Mentions · last 7 days
2026-06-11: 4 posts2026-06-12: 3 posts2026-06-13: 0 posts2026-06-14: 0 posts2026-06-15: 81 posts2026-06-16: 36 posts2026-06-17: 187 posts311+151%
Price updated 12h ago·X counts updated 2d ago
ELELTX
Elicio Therapeutics, Inc.$ELTX
$3.85-18.26%311 posts+151%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $ELTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-06-19

Falling on heavy selling — points lower unless it turns around.

Cancer-immunotherapy microcap with mixed clinical results and a fresh stack of securities investigations; tail risks dominate the asymmetry near term.

Elicio Therapeutics is the clinical-stage cancer-immunotherapy microcap that just reported multiple complete responses with ELI-002 7P followed by checkpoint inhibitor therapy — durable-response framing is the headline bull case. But the same week brought a 'pancreatic cancer study disappoints' headline (June 15) and two separate firms (Holzer & Holzer, SueWallSt) launching investigations of officers and directors. The stock is volatile — alerted at $3.05 and hit $6.49 for a 112% gain per the X chatter — purely retail-momentum framing. At $3.85 the stock is -52% YTD and -52% T12M on a $90M market cap. Gross margin 0% and ROE -27% are clinical-stage; debt-to-equity -9.98 reflects negative book equity from accumulated deficit. The bear case is straightforward: a study-disappointment plus multiple law-firm investigations at this market cap is a textbook stack of red flags; the offsetting case is that real durable complete responses in pancreatic cancer (even mixed) are clinically meaningful, and a sub-$100M cap leaves room for M&A interest.

micro cap risk

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment7 posts analyzed · as of 2026-06-18

Elicio Therapeutics ($ELTX) was alerted at $3.05 and hit $6.49 for a 112% gain with traders citing key levels of $6, $6.20, and $6.30 for continued upside. Multiple day-trader watchlists flag ELTX as a small-cap momentum runner alongside RXT and OBAI. Tone is purely speculative-momentum with the closes-above $6 framing as the next breakout trigger.

Read the AI verdict + X sentiment for $ELTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ELTX.

Biotechnology · Healthcare

GLP-1 obesity pipeline competition is the dominant structural driver — the 'next phase' of obesity drugs (oral formulations, differentiated mechanisms) is reshaping clinical bets for NVO competitors. Gene editing (CRSP, BEAM, NTLA, PRME) is transitioning from clinical to commercial-maturation phase with Casgevy scaling; oncology binary events (IBRX, ALLO, KURA) define the near-term calendar.

See how Biotechnology shapes $ELTX

  • Where the industry is in its cycle and the catalysts moving it now
  • What this means specifically for $ELTX's next move
  • Peer-basket or ETF benchmark you can use to gut-check the read
Free, forever. No credit card.

Top industry ETF

$IBBiShares Biotechnology ETF
+2.4%YTD
+38.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-228%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-42.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-27.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-10.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 11, 2026$-0.65$-0.49-32.7%
Q4 2025Mar 12, 2026$-0.49$-0.47-4.3%
Q3 2025Nov 13, 2025$-0.60$-0.62+3.2%
Q2 2025Aug 7, 2025$-0.66$-0.69+4.3%
Next earningsThu, Aug 6·consensus EPS $-0.53

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.65$-11.6M
Q4 FY25$0———$-0.45$-6.8M
Q3 FY25$0———$-0.60$-11.1M
Q2 FY25$0———$-0.66$-8.9M

Forward consensus

5-year forecast · up to 3 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$20.0M$20.0M – $20.0M-$2.06-$2.27 – -$1.853
FY27$0$0 – $0-$2.38-$2.38 – -$2.380
FY28$0$0 – $0-$2.70-$3.30 – -$2.100
FY29$0$0 – $0-$4.00-$4.00 – -$4.000
FY30$60.7M$60.7M – $60.7M-$2.90-$2.90 – -$2.901

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.9%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-64.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-61.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 8.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today60.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.145-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Know if $ELTX is setting up — or just chopping

  • Volume multiple vs 30-day baseline — catch unusual interest before the move
  • Position vs 50d & 200d MAs and 52-week range — trend direction at a glance
  • Float bucket, beta, and active-offering flags — what kind of stock you're trading
Free, forever. No credit card.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 4 other (4 awards) in window

See when $ELTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KAgreement terminatedMar 168-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated
424B5Prospectus supplement (offering)Mar 16424B5
S-3/AShelf registrationMar 12S-3/A
S-3/AShelf registrationMar 2S-3/A
S-3Shelf registrationFeb 27S-3
+ 11 other (2 routine 8-Ks · 2 earnings 8-Ks · 2 10-Ks · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drugbenzinga.com·2d agoElicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancerglobenewswire.com·2d agoElicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)prnewswire.com·3d agoElicio Therapeutics Pancreatic Cancer Study Disappointsbenzinga.com·4d agoELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc.globenewswire.com·4d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALLO$NVO$AURA$HUMA$ALT$IBRX$QURE$RXRX
Voices on X · top 7 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport